Skip to main content
Hit enter to search or ESC to close
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
© 2022 VHIR Annual Report 2021.
Six Top Stories
Facts & Figures
Partners and Acknowledgements
VHIR Annual Report 2021